Takeda Pharmaceutical Company Limited - SIC # 8922 -

Ticker Exchange SIC # Website Latest Ticker
TAK New York 8922 www.takeda.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Takeda Pharmaceutical Company Limited

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - Jan 21st, 2025 1:00 pm
Takeda Recognized as a Top Employer in Canada for Third Consecutive Year - Jan 21st, 2025 1:00 pm
Health Canada gives Takeda’s mCRC capsules market authorisation - Jan 21st, 2025 11:43 am
Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC) - Jan 20th, 2025 1:00 pm
Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025. - Jan 2nd, 2025 9:03 pm
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency - Dec 27th, 2024 12:59 pm
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia - Dec 27th, 2024 6:00 am
Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative - Dec 19th, 2024 1:02 pm
Takeda Announces Subsidiary Liquidation and Merger Completion - Dec 19th, 2024 11:32 am
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) - Dec 13th, 2024 12:00 am
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas - Dec 12th, 2024 10:30 pm
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug - Dec 4th, 2024 11:07 am
Takeda licensed for anaemia therapy by Keros Therapeutics - Dec 4th, 2024 9:31 am
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst - Dec 3rd, 2024 5:37 pm
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept - Dec 3rd, 2024 12:00 pm
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Dec 3rd, 2024 12:00 pm
Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook - Dec 3rd, 2024 11:30 am
Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now? - Nov 30th, 2024 9:29 pm
Takeda Canada co-sponsors grant to boost IBD clinical research - Nov 29th, 2024 1:08 pm
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan - Nov 22nd, 2024 4:30 am